Bast RC Jr

No ORCID on file · 11 papers in corpus
review 2019
Current oncology reports ·doi:10.1007/s11912-019-0816-0

PURPOSE OF REVIEW: Both conventional and novel approaches to early detection of ovarian cancer are reviewed in the context of new developments in our understanding of ovarian cancer biology. RECENT FINDINGS: While CA125 as a single value l…

review 2018
Hematology/oncology clinics of North America ·doi:10.1016/j.hoc.2018.07.003

Early detection of ovarian cancer could reduce mortality by 10% to 30%. Effective screening requires high sensitivity (>75%) and extremely high specificity (99.7%). Clinical trials suggest the best specificity is achieved with 2-stage strat…

other 2018
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology ·doi:10.1002/uog.17557

The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) recently reported a reduction in the average overall mortality among ovarian cancer patients screened with an annual sequential, multimodal strategy that tracked b…

review 2013
Oncology (Williston Park, N.Y.)

HE4 (human epididymis protein 4) is overexpressed in both ovarian and endometrial cancers. Levels of the shed HE4 protein are elevated in sera from ovarian and endometrial cancer patients. HE4 is less frequently elevated than cancer antigen…

observational 2012
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2011.12.029

OBJECTIVE: The human epididymis protein 4 (HE4) is a novel biomarker for ovarian cancer. This study measured the HE4 and CA125 levels in women with benign gynecological disorders. STUDY DESIGN: Sera were obtained from women prior to surger…

meta-analysis 2012
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2011.12.028

OBJECTIVE: The purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women. STUDY DESIGN: HE4 levels were measured in healthy women and analyzed by age, menopausal status, and pre…

review 2011
Annals of oncology : official journal of the European Society for Medical Oncology ·doi:10.1093/annonc/mdr516

Cytoreductive surgery and empirical combination chemotherapy have improved 5-year survival for ovarian cancer patients, but have not increased the overall rate of cure. Poor outcomes relate, at least in part, to late diagnosis and to the pe…

review 1998
The International journal of biological markers ·doi:10.1177/172460089801300402

Over the last 15 years, substantial progress has been made in understanding the potential and the limitations of the CA 125 assay. More than 2000 papers have been published concerning laboratory and clinical studies of CA 125. The original …

review 1989
Human Reproduction ·doi:10.1093/oxfordjournals.humrep.a136832

CA 125 is an antigenic determinant on a high-molecular-weight glycoprotein recognized by a monoclonal antibody which was raised using an ovarian cancer cell line as an immunogen. During the last 5 years the studies reviewed in this paper ha…

observational 1986
Fertility and sterility ·doi:10.1016/s0015-0282(16)49333-7

CA-125 is a high-molecular-weight glycoprotein that is expressed on the cell surface of some derivatives of embryonic coelomic epithelium. Based on results of an immunoradiometric assay developed to detect CA-125 in peripheral blood, 82% of…

other 1985
Cancer treatment reports

Recombinant leukocyte alpha interferon (rIFN-alpha A; Hoffmann-La Roche, Inc) was administered to 15 patients with recurrent or persistent ovarian carcinoma. All patients had been previously treated with surgery and combination chemotherapy…